Celltrion said on the 4th that OMLYCLO, which treats asthma and urticaria, is expanding its market in Spain. OMLYCLO is a biosimilar of XOLAIR developed by Swiss drugmaker Novartis.
Celltrion's Spanish subsidiary was selected as the No. 1 supplier in a public tender in Catalonia at the end of last year. Catalonia is considered the largest supply region locally due to its high population density. OMLYCLO is also set to be supplied to the Basque Country. The company said it was chosen as the top bidder in a Basque Country public tender as well and signed a supply contract on the 1st of last month.
Celltrion's Spanish subsidiary launched OMLYCLO through direct sales in September last year. OMLYCLO is prescribed at about 260 public and private hospitals in Spain. The Spanish subsidiary estimates that OMLYCLO captured a 60% share of the local market by the end of last year, three months after its launch.
Celltrion plans to push for broader OMLYCLO prescriptions across Europe. In Norway, OMLYCLO posted a 17% market share in its first quarter of sales. In the Netherlands, home to the European Medicines Agency (EMA), the company won a hospital group tender and secured supply volume covering as much as 70% of the overall market.
Kang Seok-hoon, head of Celltrion's Spanish subsidiary, said, "OMLYCLO is improving patient access to treatment in Spain based on supply stability," adding, "As we participate in upcoming public tenders and full-scale delivery of awarded volumes begins, prescriptions will increase."